Clinical Trials Directory

Trials / Completed

CompletedNCT04728100

LQT and Smartphone/Smartwatch

Smartphone and Smartwatch Based ECG for Patients With Congenital Long QT Syndrome

Status
Completed
Phase
Study type
Observational
Enrollment
111 (actual)
Sponsor
Hospices Civils de Lyon · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Congenital long QT syndrome (LQTS) is a rare genetic disorder characterized by prolongation of the corrected QT interval (QTc) on the electrocardiogram. LQTS is associated with a risk of syncope or sudden death from ventricular arrhythmia. The increase in the duration of the corrected QT interval and / or changes in the morphology of the T wave on the electrocardiogram are markers of an increased risk of sudden death and syncope. Recently, a personal portable 6-lead device (DI, DII, DIII, aVF, aVL and aVR) connected to the patient's smartphone has entered the market (KARDIA MOBILE 6L, AliveCor, Mountain View, CALIFORNIA, USA). The APPLE WATCH Series 6 (Apple, Cupertino, CA, USA) can also record an ECG. If the device is designed to record a single lead (DI), several works have shown that it is possible to record 9 leads (DI, DII, DIII, V1, V2, V3, V4, V5 and V6) by moving simply the device (Spaccarotella CAS et al. JAMA Cardiology 2020). These devices were originally designed to screen for atrial fibrillation, but they produce accurate 6- and 9-lead ECGs and could potentially allow ambulatory ECG monitoring of patients with LQTS.

Conditions

Interventions

TypeNameDescription
OTHERLQTPatients with LQT syndrome diagnosis.

Timeline

Start date
2021-03-22
Primary completion
2023-06-12
Completion
2023-06-12
First posted
2021-01-28
Last updated
2023-11-07

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04728100. Inclusion in this directory is not an endorsement.